Quercetin in Coronary Artery By-pass Surgery (NCT04907253) | Clinical Trial Compass
CompletedPhase 2
Quercetin in Coronary Artery By-pass Surgery
Canada100 participantsStarted 2021-06-04
Plain-language summary
The purpose of this study is to test the anti-inflammatory and anti-senescence effects of quercetin during coronary artery by-pass graft surgery.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* to be able to speak French or English;
* to be able to give free and enlighten consent;
* be hospitalized and waiting for a cardiac surgery of revascularization;
* to have had a myocardial infarction (MI) within the past 30 days or to be in a state of stable angina before the surgery.
Exclusion Criteria:
* to be in a stable state without MI in the last 30 days;
* have a cardiac surgery concomitant to the cardiac surgery of revascularization;
* have an infection in the last 30 days;
* to have renal insufficiency (GFR less than 30);
* to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);
* to have a known cirrhosis;
* to have a past history of breast cancer or other tumors estrogen-dependent;
* to be intolerant to flavonoids, niacine or ascorbic acid;
* take quinolone;
* need for a quinolone during post-op;
* not being able to give a free and enlighten consent;
* not being able to speak French of English;
* take quercetin as a supplement.
What they're measuring
1
Quercetin-associated Change in Surgery-associated Inflammation
Timeframe: Baseline, 1 day and 4 days post-surgery
2
Quercetin-associated Change in Surgery-associated Marker of Senescence
Timeframe: Baseline, 1 day and 4 days post-surgery